BioSpace News Archive

You must have these signs of leadership whether you’re considering moving into a leadership position or already leading a team. Check if you have them.

Shares of Synlogic, Inc. are climbing this morning after the New York Times highlighted the company’s proprietary synthetic biotics being used to treat patients with PKU. The company also released positive interim data from an ongoing study of its PKU treatment.

Each year, Peter Drucker’s Drucker Institute generates its Management Top 250, evaluating companies based on what it calls five dimensions of corporate performance. Those five dimensions are Customer Satisfaction, Employee Engagement and Development, Innovation, Social Responsibility and Financial Strength.

MannKind Corporation, based in Westlake Village, California, and United Therapeutics, located in Silver Spring, Maryland, signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil.

Shares of Paris-based Abivax have shot up more than 8 percent this morning after the company posted positive mid-stage results for its ulcerative colitis treatment, ABX464.

Eight so-called “superstar scientists” based in Cambridge, UK, have co-founded an investment fund dubbed Ahren with 100 million pounds, so far. One of their first investments is in biotech company Cambridge Epigenetix for $10 million.

Two years after charges were filed by the federal government, former GlaxoSmithKline researcher Yu Xue pled guilty to a single conspiracy charge related to emailing company trade secrets that would have been used to set up competing companies in China.

As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.

The development of alternative therapies to combat antibiotic-resistant bacteria has attracted more than €4 million in grants and private investments for Vienna-based biotech company PhagoMed Biopharma GmbH (PhagoMed).

On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.